Drugs
Medivation's Alzheimer Trial Data in Early March: Biobuzz
Spectrum Licenses Lymphoma Drug
Spectrum Pharmaceuticals(SPPI) announced Tuesday that it has partnered with Danish drug firm TopoTarget to co-develop the lymphoma drug belinostat. Belinostat is currently in a pivotal, phase II study in patients with peripheral T-cell lymphoma. Under the agreement, Spectrum paid $30 million upfront to TopoTarget in exchange for belinostat rights to North America, India and an option for China. TopoTarget retains rights to the drug in Europe and the rest of the world. Spectrum is on the hook for another $320 million in potential milestone payments to TopoTarget depending on belinostat's future development. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |
Connect with TheStreet